Twelve patients with refractory (8 pts) and relapsing (4 pts) myeloma were treated with Peptichemio. Teniposide and high-dose dexamethasone. Eight patients experienced an objective response (5 out 8 with refractory and 3 out 4 with relapsing disease) with a median duration of 10+ months. Overall toxicity was mild to moderate and chiefly haematological. Our preliminary results seem very promising and justify a larger phase II study with this regimen.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
peptichemio teniposide
8
teniposide high-dose
8
high-dose dexamethasone
8
dexamethasone active
4
active combination
4
combination relapsing
4
relapsing refractory
4
refractory multiple
4
multiple myeloma
4
myeloma pilot
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!